Theriva Biologicsの空売り状況は、投資家がTheriva Biologicsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Theriva Biologics (AMEX:TOVX) 株価情報, 空売り情報

Theriva Biologics

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Theriva Biologics Inc

Earnings

Earnings Beats

Earnings Misses

News

Dillard's Q1 EPS $10.39 Beats $9.14 Estimate, Sales $1.53B Miss $1.54B Estimate

Scotiabank analyst Mike Rizvanovic assumes Toronto-Dominion Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TD#TSX">TD</a>) with a Sector Perform rating and announces Price Target of C$90.

Price Target

Initiation

Analyst Ratings

TSX:TD

Scotiabank Assumes Toronto-Dominion Bank at Sector Perform, Announces Price Target of C$90

Graphex Group Limited ("Graphex Group" or the "Company") (HKSE: 6128)) announced today that the NYSE American LLC (the "New York Exchange") has issued a delisting letter for its American Depositary Shares (ADSs) and suspended trading with the symbol "GRFX" as of May 14, 2025. As previously reported, the Company is not in compliance with Sections 134 and 1101 of the NYSE American Company Guide ("Company Guide") since it failed to timely file with the Securities and Exchange Commission ("SEC") its Form 20-F for the year ended December 31, 2023 (the "Delayed Filing") and that the period granted by the New York Exchange to complete the Delayed Filing was May 15, 2025. The ADSs will now trade on the OTC Expert Market operated by the OTC Markets Group, Inc.

GRFX

Graphex Group Delisted From NYSE American, Trading Suspended; ADSs Move To OTC Expert Market

Needham analyst James Ricchiuti maintains Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) with a Buy and raises the price target from $28 to $30.

KRNT

Needham Maintains Buy on Kornit Digital, Raises Price Target to $30

Berkshire Hathaway CEO Warren Buffett and former vice chairman Charlie Munger's <a href="https://www.benzinga.com/personal-finance/24/12/42496912/warren-buffett-doesnt-believe-college-is-for-everyone-none-of-his-3-kids-finished-if-you-pool-their-credits-you-got-a-degree">distaste for fancy degrees</a> and business schools is well known. At the 2012 Annual Meeting, a Master of Business Administration student asked them what they considered the right way to train business leaders.
What Happened: In response, Buffett labelled much of what is taught in top-tier business schools as &#8220;the silliest stuff,&#8221; particularly in the field of investing. "It is astounding to me how the schools have focused on sort of one fad after another in finance theory. And it&#8217;s usually been very mathematically based," he said. 
He observed that the pressure to move up through the ranks frequently compels faculty members to conform rather than disrupt the status quo: "Going against the revealed wisdom of your elders—it can be very dangerous to your career path at major business schools."
Instead of technical models like modern portfolio theory or option pricing, Buffett said students should be made to take only two courses: "I would have a course on how to value a business, and I would have a course on <a href="https://www.benzinga.com/markets/25/03/44533852/what-would-buffett-do-with-markets-inches-away-from-the-extreme-fear-zone-is-it-finally-time-to-be-greedy">how to think about markets</a>."
See Also: <a href="https://www.benzinga.com/markets/equities/25/05/45342110/warren-buffetts-cash-mountain-grows-to-314-billion-as-berkshire-hathaway-emerges-as-top-treasury-bill-holder-wed-spend-100-billion-if-the-right-deal-came-along">Warren Buffett&#8217;s Cash Mountain Grows To $314 Billion As Berkshire Hathaway Emerges As Top Treasury-Bill Holder: &#8216;We&#8217;d Spend $100 Billion&#8217; If the Right Deal Came Along, Says Oracle Of Omaha</a>
Why It Matters: Buffett reiterated his belief that the <a href="https://www.benzinga.com/news/25/01/43219503/charlie-mungers-three-investment-lessons-buy-wonderful-businesses-at-fair-prices-big-money-isnt-in-buying-or-selling-its-in-waiting-good-businesses-are-ethical-businesses">core of investing</a> lies in understanding business value, not abstract models. "If you buy businesses for less than they&#8217;re worth, you&#8217;re going to make money," <a href="https://buffett.cnbc.com/video/2012/05/05/buffett-business-schools-have-made-investing-more-difficult.html">he said</a>. He also highlighted how crucial it is to recognise which businesses can be accurately valued.
He illustrated this disconnect between real-life situations and textbook knowledge by referencing Ray Kroc, the founder of McDonald&#8217;s, saying, "When Ray Kroc started McDonald's, he was nothing but the option value of what the McDonald's stock might be or something. He was thinking about whether people would buy hamburgers".
Munger added that accounting, too, has become subject to such thinking, criticizing the common use of the Black-Scholes model. "They want some kind of a standardized solution that requires them not to think too hard. And they have one," he said
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/management/25/05/45429435/warren-buffett-explains-why-he-couldnt-deny-greg-abel-the-top-job-at-berkshire-hathaway-any-longer-hes-a-natural">Warren Buffett Explains Why He Couldn&#8217;t Deny Greg Abel The Top Job At Berkshire Hathaway Any Longer: &#8216;He&#8217;s A Natural&#8217;</a></li>
</ul>
Image Via Shutterstock

Education

General

Warren Buffett Once Said Business Schools Teach 'The Silliest Stuff'—And This Is What He And Charlie Munger Would Do Instead To Train The Next Generation Of Leaders

Scotiabank analyst Meny Grauman assumes Royal Bank of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RY#TSX">RY</a>) with a Sector Outperform rating and announces Price Target of C$188.

TSX:RY

Scotiabank Assumes Royal Bank of Canada at Sector Outperform, Announces Price Target of C$188

HC Wainwright &amp; Co. analyst Kevin Dede maintains DeFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEFT#NASDAQ">DEFT</a>) with a Buy and raises the price target from $4.5 to $5.5.

DEFT

HC Wainwright & Co. Maintains Buy on DeFi Technologies, Raises Price Target to $5.5

The study also met a secondary endpoint of overall survival (OS) in patients whose tumors express PD-L1. The study is evaluating KEYTRUDA&#xAE; (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for these patients. The trial is continuing and OS for the full study population will be evaluated at a future analysis.&nbsp;

Biotech

Large Cap

Health Care

Merck's Keytruda Phase 3 KEYNOTE-B96 Trial (Also Known As ENGOT-ov65) Met Its Primary Endpoint Of Progression-free Survival For Patients With Platinum-resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 And In All Comers

Scotiabank analyst Meny Grauman assumes Canadian Imperial Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CM#TSX">CM</a>) with a Sector Outperform rating and announces Price Target of C$98.

TSX:CM

Scotiabank Assumes Canadian Imperial Bank at Sector Outperform, Announces Price Target of C$98

ITT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITT#NYSE">ITT</a>) will host its 2025 Capital Markets Day today beginning at 1 p.m. ET in New York. Chief Executive Officer and President Luca Savi, Chief Financial Officer Emmanuel Caprais and members of ITT's extended leadership team will deliver a series of presentations covering the company's differentiation through execution, innovation and M&amp;A.
In connection with its Capital Markets Day, the company also announced new 2030 long-term financial targets. ITT expects to deliver the following financial results, all compared to actual results for the year ended Dec. 31, 2024:
<ul>
<li>More than 5% average annual organic revenue growth and approximately 10% total including expected contributions from acquisitions</li>
<li>~23% adjusted operating margin on a consolidated basis, an expansion of more than 500 basis points versus 2024</li>
<li>More than $11 of adjusted earnings per share (EPS) from existing businesses</li>
<li>Additionally, ITT expects to deploy between $500-700 million per year to accretive acquisitions which the company estimates would contribute an additional $0.75 to $1.00 of EPS toward more than $12 in total by 2030</li>
<li>14% to 15% free cash flow margin</li>
</ul>

ITT Outlines 2030 Long-Term Growth Targets: ITT Forecasts 10% Revenue Growth, 23% Adj. Opt. Margin, $12+ EPS Target By 2030

HC Wainwright &amp; Co. analyst Mike Colonnese maintains IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Buy and lowers the price target from $22 to $21.

IREN

HC Wainwright & Co. Maintains Buy on IREN, Lowers Price Target to $21

On Wednesday, May 14, U.S. markets closed mixed. The S&amp;P 500 closed slightly higher after a quiet session, with investors awaiting economic data following gains earlier in the week tied to easing inflation and a U.S.-China tariff pause.
Tech stocks rose on AI deals in the Middle East, while trade uncertainty and Fed signals kept markets cautious. The Dow slipped, and the Nasdaq advanced.
In economic data, U.S. mortgage applications rose slightly in the week ending May 9, up 1.1% from the previous week, easing after an 11% jump the week before.
Most S&amp;P 500 sectors fell Wednesday, led by losses in health care, materials, and real estate, while tech and communication stocks gained.
The Dow Jones Industrial Average declined 0.21% to 42,051.06, the S&amp;P 500 gained 0.10% to 5,892.58, and the Nasdaq surged 0.71% to 19,146.81.
Asia Markets Today
<ul class="wp-block-list">
<li>On Thursday, Japan's Nikkei 225 closed 0.88% lower at 37,793.00, led by losses in the Paper &amp; Pulp, Transport, and Communication sectors.</li>
<li>Australia's S&amp;P/ASX 200 gained 0.22%, ending the session at 8,297.50, led by gains in the IT, Financials, and Consumer Discretionary sectors.</li>
<li>India's Nifty 50 was up 1.52% at 25,044.25, and Nifty 500 rose 1.24% to 22,777.70.</li>
<li>China's Shanghai Composite declined 0.68% to 3,380.82, and Shanghai Shenzhen CSI 300 was down 0.91% at 3,907.20.</li>
<li>Hong Kong's Hang Seng closed the session 0.79% lower at 23,453.16.</li>
</ul>
Eurozone at 06:00 AM ET
<ul class="wp-block-list">
<li>The European STOXX 50 index was down 0.49%.</li>
<li>Germany's DAX index declined 0.10%.</li>
<li>France's CAC 40 fell 0.22%.</li>
<li>The U.K.'s FTSE 100 index traded higher by 0.08%.</li>
</ul>
Commodities at 06:00 AM ET
<ul class="wp-block-list">
<li>Crude Oil WTI was trading lower by 3.71% at $60.81/bbl, and Brent was down 3.50% at $63.81/bbl.</li>
<li>Oil prices plunged nearly 4% on hopes of a U.S.-Iran nuclear deal that could boost supply, while global stocks paused after a rally driven by trade truce optimism and Middle East deals.</li>
<li>Natural Gas declined 0.23% to $3.486.</li>
<li>Gold was trading lower by 0.34% at $3,177.70, Silver was down 0.64% to $32.230, and Copper fell 0.53% to $4.6263.</li>
</ul>
U.S. Futures at 06:00 AM ET
Dow futures were down 0.31%, S&amp;P 500 futures declined 0.49%, and Nasdaq 100 futures fell 0.67%.
Forex at 06:00 AM ET
The U.S. Dollar Index declined 0.28% to 100.79, USD/JPY was down 0.55% to 145.87, and USD/AUD rose 0.22% to 1.5589.
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Slips; Dollar Slides Amid Fed Uncertainty - Global Markets Today While US Slept

Leveraging Infosys' global expertise in digital transformation, the collaboration will modernize the bank's IT landscape, enhance customer experience, and optimize operational efficiency
BENGALURU, India, May 15, 2025 /PRNewswire/ -- <a href="https://www.infosys.com/">Infosys</a> (NSE: INFY) (BSE: INFY) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>), a global leader in next-generation digital services and consulting, today announced an expansion of its strategic collaboration with <a href="https://apc01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.dnb.no%2Fen&amp;data=05%7C02%7Cmelvin.alex%40infosys.com%7C089ecf784317441cb58e08dd913d0d2f%7C63ce7d592f3e42cda8ccbe764cff5eb6%7C0%7C0%7C638826413679085166%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=8Ef%2Bx7Ufu1W1v3Q30pXzVte%2Fjtq7Hv7VGRB2%2BlsP0T4%3D&amp;reserved=0">DNB Bank ASA</a>&nbsp;(DNB), Norway's largest bank, to accelerate the bank's digital transformation. The collaboration will leverage&nbsp;Infosys' services, solutions, and platforms, including the <a href="https://apc01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.finacle.com%2F&amp;data=05%7C02%7Cmelvin.alex%40infosys.com%7C089ecf784317441cb58e08dd913d0d2f%7C63ce7d592f3e42cda8ccbe764cff5eb6%7C0%7C0%7C638826413679113286%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=nP9hsDzNnfUwZ9Fb%2FvMw2TL1VF98KIzXBlr%2BtifZ%2Bvk%3D&amp;reserved=0">Infosys Finacle</a> platform to accelerate their IT modernization journey, improve resilience, and deliver enhanced customer experience.

INFY

Infosys Expands Strategic Collaboration With DNB Bank To Accelerate Bank's Digital Transformation

Keyera (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KEY#TSX">KEY</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.52 by 9.62 percent. This is a 83.87 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $1.76 billion which missed the analyst consensus estimate of $1.78 billion by 1.12 percent. This is a 15.71 percent increase over sales of $1.52 billion the same period last year.

TSX:KEY

Keyera Q1 EPS $0.57 Beats $0.52 Estimate, Sales $1.76B Miss $1.78B Estimate

Needham analyst Ryan Koontz maintains Radcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDCM#NASDAQ">RDCM</a>) with a Buy and raises the price target from $17 to $18.

RDCM

Needham Maintains Buy on Radcom, Raises Price Target to $18

BT Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBD#NASDAQ">BTBD</a>) reported quarterly losses of $(0.05) per share. This is a 28.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported $3.23 million in sales this quarter. This is a 1.28 percent increase over sales of $3.19 million the same period last year.

BTBD

BT Brands Q1 EPS $(0.05) Up From $(0.07) YoY, Sales $3.23M Up From $3.19M YoY

The quarterly cash dividend amount of $0.18 per share will be paid on June 16, 2025, to shareholders of record at the close of business on May 30, 2025.

Dividends

Advanced Drainage Systems Raises Annual Dividend By 13% To $0.72 Per Share; Sets $0.18 Quarterly Payout For June 16

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) with a Buy and maintains $29 price target.

Reiteration

CELC

Needham Reiterates Buy on Celcuity, Maintains $29 Price Target

Citigroup analyst John Yu initiates coverage on Webtoon Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) with a Buy rating and announces Price Target of $11.

WBTN

Citigroup Initiates Coverage On Webtoon Entertainment with Buy Rating, Announces Price Target of $11

GPUS

Hyperscale Data Plans To Resume Bitcoin Mining Operations At One Of Its Two Montana Sites On Or Around June 10, 2025

Press Releases

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company's Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

Financing

Theriva Biologics Announces Closing of $7.5 Million Public Offering

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

TOVX

Aditxt

Apollomics

Aptevo Therapeutics

Bone Biologics

Entero Therapeutics

Genprex

GRI Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

NuCana

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Tharimmune

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

Screenshot 2024-08-23 at 5.34.20 PM

Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma

Screenshot 2024-07-31 at 5.25.33 PM

Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers

Screenshot 2024-07-08 at 2.14.39 PM

Disproportionate Rise In Pancreatic Cancer Among Young Women Highlights High Unmet Need To Find Safe, Effective Treatments – Is Hope On The Horizon?

Screenshot 2024-06-06 at 5.27.01 PM

Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer

Screenshot 2024-04-16 at 5.31.31 PM

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers

Screenshot 2024-03-26 at 11.16.22 PM

Utilizing Common Viruses To Combat Dangerous Cancers – Hear From The Leaders Of This Biotech

Screenshot 2024-03-13 at 5.34.18 PM

How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need

Screenshot 2024-03-05 at 6.31.45 PM

CADL

CGON

CLDI

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Comments

Theriva Biologics

空売り

Theriva Biologics (AMEX:TOVX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル